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1. Introduction 
Life expectancy increases in developed countries and results in a high prevalence of age-
related diseases namely in women. Elderly subjects generate a huge demand on the social 
and health services linked to their disability and dependence. Besides the own effects of 
aging, the estrogenic deficiency, especially during menopause, is the major cause of 
degenerative diseases such as osteoporosis, skin aging, Alzheimer’s disease and 
osteoarthritis (OA) (Antonicelli et al., 2008; Candore et al., 2006; Elders, 2000; Felson & 
Nevitt, 1998; Pietschmann et al., 2008; Stovall & Pinkerton, 2008). OA is a worldwide public 
health problem which may affect different sites of the skeleton. In the Western world, at 
least 10% of the population has OA symptoms and 80% of the population will be potentially 
affected after the age of 70 years. Knee OA represents one of the major causes of morbidity 
and disability in relation to the worsening of quality of life (Elders, 2000). Pathogenesis of 
knee OA involves multiple factors including gender, weight, and genetics. Although age-
dependent degenerative pathologies, especially OA, involve complex mechanisms in which 
the imbalance of the cytokines/growth factors plays a crucial role, it is more and more 
obvious that estrogens participate, with their receptors and modulators, to all of these 
diseases affecting connective tissues (Calleja-Agius & Brincat, 2009). Estrogens are steroidal 
hormones irreversibly synthesized from androgens via a crucial enzyme of steroidogenesis 
called aromatase, a member of cytochrome P450 superfamily, encoded by the CYP19 gene 
and being expressed in both sexes of many species (Simpson, 2003).  
Although non genomic action of estrogens is now recognized but these sexual hormones act 
often as signaling molecules that exert their effects by binding to estrogen receptors (ER) 
within the cells.  
The estrogen-receptor complex interacts then with DNA to change the expression of 
estrogen-responsive genes. The two known estrogen receptors, ER and ER, are present in 
numerous tissues other than those associated with reproduction, including bone, liver, 
heart, brain and cartilage and being selectively expressed in some targets; for instance ER is 
selectively expressed in lung and intestine. The presence of ER and ER was detected in 
articular chondrocytes of different species, especially in human, rat, pig, cow and rabbit 
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(Classen et al., 2001; Dayani et al., 1988; Oshima et al., 2007; Ushiyama et al., 1999). The 
action of 17-estradiol (17-E2) on the cartilage appears to be intimately linked to the sex of 
individuals since it was shown that the binding capacity of 17-E2 to its receptor was 
significantly higher in chondrocytes derived from male rather than female individuals 
(Nasatzky et al., 1994). In addition, 17-E2 can stimulate the nuclear expression of its own 
receptors in chondrocytes and create therefore a loop that reinforces the activation effects of 
the hormone in this cell type (Richmond et al., 2000). Moreover, a strong correlation was 
found between the polymorphism of ESR1 gene encoding ER and increased risk of OA in 
several populations (Bergink et al. 2003; Valdes et al., 2006). All these observations tend to 
prove that the cartilage is an estrogen-sensitive tissue, in which 17-E2 would be likely to 
play a preponderant role in regulating chondrocyte homeostasis in joint diseases such as 
OA. 
Even thought hormone replacement therapy (HRT) is the most efficient treatment against, at 
least, some of the degenerative pathologies mentioned above but studies confirm that risks 
linked to HRT can exceed the discounted benefits. As a consequence, it becomes important 
to address the question of the age-associated disorders and to find new targets to treat them. 
Selective Estrogen Receptor Modulators (SERM) like tamoxifen, raloxifen, fulvestrant and 
genistein have shown to be useful and attracted the attention of researchers (Cotter & 
Cashman, 2003; Khalil, 2010; Riggs & Hartmann 2003).  A characteristic that distinguishes 
these substances from pure receptor agonists and antagonists is that their action is different 
in various tissues, thereby giving the possibility to selectively inhibit or stimulate estrogen-
like action in various tissues. For instance tamoxifen (a first generation SERM) and raloxifen 
have been clinically used as antagonists of ER against breast cancer while they could be 
potentially agonists in bone and growth plate (Chagin et al, 2007; Nilsson et al, 2003). It has 
been proposed that these SERM could be used to replace natural estrogens to induce growth 
plate fusion reducing thereby the final height in girls expected to achieve extreme tall 
stature. Moreover, phytoestrogens (flavones, isoflavones, lignans) have aroused much 
interest as natural SERM and potential substitutes in the hormonal treatment of post-
menopausal women, but they require much further investigation regarding their 
mechanism(s) of action and their safety (Dodin et al, 2003). 
2. Estrogen synthesis and action 
2.1 Estrogen synthesis via aromatase 
Estrogens are steroidal hormones composed from 18 atoms of carbon and produced 
essentially in gonads, ovary and testis, but also in non reproductive tissues such as bone and 
adipose tissue. These lipophilic compounds irreversibly synthesized from androgens via a 
crucial enzyme of steroidogenesis called aromatase, a member of cytochrome P450 
superfamily, encoded by the CYP19 gene and being expressed in both sexes of many 
species. In pre-menopoausal women, estrogens such as 17-E2 (the more estrogenic) and 
estrone are synthesized in ovary during follicular phase whereas estriol being produced 
essentially by placenta during pregnancy. After menopause, when ovary activity 
disappears, production of 17-E2 from testosterone via aromatase is assumed by peripheral 
tissues like liver, adipose tissue, bone, vascular endothelium, chondrocyte and synovial cells 
(Simpson, 2003; Takeuchi et al., 2007; Tanko et al., 2008). Consequently, circulating 17-E2 
concentrations decrease drastically to 0.04-0.21 nM to reach those found in man (Chambliss 
& Shaul, 2002). Thus, estrogen action being localized and switch from endocrine to auto-, 
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intra- and/or paracrine actions. Due to their lipophilic feature, estrogen can diffuse into the 
cell through plasma membrane and induce estrogen-dependent intracellular signaling 
pathways and/or bind the intracellular receptors especially ER stimulating an estrogen-
dependent response in target cells. 
2.2 ER structure 
In mammals, estrogens produced locally in different tissues, may exert various biological 
effects but are also responsible of the development of some pathological process such as 
hormone-dependent cancers. Estrogens exert their physiological and pathological effects 
through specific receptors considered as nuclear factors by binding target genes at a specific 
cis sequence called Estrogen Responsive Element (ERE).  
The first study on estrogen receptor, published by Toft & Groski in 1966, demonstrated that 
a specific protein of rat uterus was able to bind specifically estrogens. Later, the gene of this 
protein has been cloned (Walter et al., 1985) and sequenced (Green et al., 1986) from 
mammal cancer epithelium (MCF-7) of a patient suffering from breast cancer. This protein is 
now recognized as ER. A second gene (ER) has been also cloned from a cDNA library of 
the rat prostatic cells (Kuiper et al., 1996), being expressed selectively in some tissues and 
presenting more affinity for phytoestrogens. 
It is now established that the majority of the normal and pathological action of estrogens 
is generally mediated through these two estrogen receptors ERand ER which are 
members of nuclear receptor super family including progesterone, glucocorticoids, 
androgens and vitamin D receptors (Nuclear Receptor Nomenclature Committee, 1999; 
Germain et al., 2006; Mangelsdorf et al., 1995). In human, ERis encoded by ESR1 gene 
located on chromosome 6 (6q25.1) whereas ER is encoded by ESR2 gene located on 
chromosome 14 (14q23.2). Both ESR1 and ESR2 genes encoding the estrogen receptor may 
undergo alternative splicing of mRNA. Most of these transcripts differ only in their 5'UTR 
(Untranslated Region) and will be mainly translated into a long form of ER, recognized as 
ER66 (Flouriot et al., 1998). However, a second form of ER protein, derived from 
alternative splicing of exon 1A mRNA or a site of alternative translation initiation (AUG 
codon 174) was discovered and named ER46 (Barrailler et al. 1999; Flouriot et al., 2000). 
After translation, the 46 kDa isoform is truncated of the 173 first amino acids of the long 
form of 66 kDa. ER46 protein is thus composed of 422 amino acids, whereas ER66 has 
595 amino acids. Both ER isoforms are capable of inducing a physiological response after 
ligand binding. The 46 kDa isoform can heterodimerize with ER66 and competitively 
inhibit the functions of ligand-independent trans activation of the long form of the receptor 
(Flouriot et al., 2000). 
ERand ER530 amino acids) are structurally organized in six distinct functional domains 
(A to F) (Fig. 1). There are structural and functional similarities more or less strong between 
ER and ER whose homology percentages vary significantly depending on the area 
considered. DNA binding domain (DBD) is conserved at about 97%, which means that both 
receptors can bind the same cis nucleotide sequences and thus activate transcription 
ofidentical target genes. However, there is only 55% homology at the level of ligand 
binding domain (LBD), indicating that ER and ER have different ligand binding 
specificity. Finally, ER has only a truncated form of ligand-independent trans activation 
domain (AF-1), thus limiting its trans activation ability (Hall & McDonnell, 1999; Pearce & 
Jordan, 2004).  
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Fig. 1. Structures and functional domains of estrogen receptors (ER) 
Structures, functional domains and sequence homology percentage (italic) of  and  isoforms. AF-1, 
ligand-independent trans activation domain; AF-2, ligand-dependent trans activation domain; 
DBD, DNA Binding Domain; hsp90, heat-shock protein 90; LBD, Ligand Binding Domain; NLS, Nuclear 
Localization Signal. These 3 isoforms, ERα46, ERα66 and ER┚ are expressed in articular chondrocytes. 
2.3 Genomic and non genomic action of estrogen 
It is well established that estrogens act at target genes level to modulate their transcription 
via ER binding, so playing a transcriptional factor role recognized as ligand-dependent 
mechanism (Jensen & DeSombre, 1973). However, estrogen action becomes more 
complicated following the discovery of ER, or different ER and ER isoforms but also 
with the identification of new plasma-associated membrane receptors. ER and ER 
regulate thus estrogen-dependent genes expression through two distinct mechanisms: ERE-
dependent genomic pathway and ERE-independent genomic pathway. 
2.3.1 ERE-dependent genomic pathway 
In this mechanism ER and ER, following ligand fixation (estrogen, phytoestrogen, SERM), 
are subjected to homo- or hetero-dimerization, then ligand/ER complex move to the nucleus 
to bind directly ERE cis element (AGGTCAxxxTGACCT) (Hall et al., 2001) present in the 
promoter of target genes (Fig. 2). The determination of consensus sequences ERE and the 
fixation of ER will help to recruit transcriptional factors such as FOXA1 (Forkhead Box A1) or 
GATA4 (GATA binding protein 4), which will first ensure the chromatin remodeling 
necessary for ER binding. Ligand binding also allows the recruitment of transcription cofactors 
such as SRC-1 (Steroid Receptor Coactivator-1), GRIP-1 (Glucocorticoid Receptor Interacting 
Protein-1), CBP (CREB Binding Protein)/p300, or TRAP220 (Thyroid Hormone Receptor 
Activating Protein 220) (McKenna et al., 1999). The classic genomic pathway requires the 
activity of the two trans activation domains AF-1 and AF-2 that will allow the sequential and 
cyclic recruitment of different co-factors of transcription (Metivier et al., 2001). 
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2.3.2 ERE-independent genomic pathway 
In this pathway, ERs will follow the classical mechanism described above except that they 
interact at the nuclear level with various transcriptional activator or repressor factors to 
regulate transcription of many estrogen-dependent genes that lack an ERE (Kushner et al., 
2000; Paech et al., 1997; Sabbah et al., 1999; Safe, 2001). 
Indeed, most estrogen-dependent genes have not necessarily in their regulatory regions a 
consensus ERE sequence. Therefore, estrogen will be involved in signaling pathways called 
ERE-independent which imply an interaction of ER with promoter of target gene through 
other transcription factors. In this case, the region of the receptor DBD does not bind to 
DNA, but participates in protein-protein interactions or recruitment of co-regulatory 
proteins to regulate expression of many genes. This mechanism of action is frequently used 
by nuclear receptors, which significantly complicates the decrypting of the effects induced 
by the ER (Gottlicher et al., 1998).  Many of ER/protein interactions, which occur in cells to 
regulate transcription of many target genes, are composed for example of ER/AP-1 complex 
(c-Fos/c-Jun) (Ascenzi et al., 2006; Duan et al., 2008; Kushner et al. 2000; Matthews et al. 
2006 ; Paech et al., 1997, Uht et al 1997; Webb et al., 1999,), ER/Sp complex (Ascenzi et al., 
2006; He et al., 2005; Kim et al., 2003; Saville et al., 2000; Stoner et al., 2004), and ER/NF-B 
complex (Galien & Garcia, 1997; Stein & Yang, 1995). This latter is the only known 
mechanism of transcriptional repression induced by ER (Fig. 2). 
For instance, after being activated by 17-E2 binding, ER interact with the transcription 
factor NF-B to control the transcriptional repression of certain genes such as IL-6 gene, 
which is involved in cartilage catabolism. Furthermore, in articular chondrocytes, it has been 
shown that 17-E2 can counteract the effects of IL-1 by inhibiting nuclear translocation of 
the p65 subunit of NF-B and therefore, binding of p65 to inducible nitric oxide synthase 
(iNOS) gene promoter (Richette et al., 2007). In addition, it has been suggested that ER and 
NF-B compete for binding to the same transcriptional co-activators (p300/CBP and PCAF), 
and that in the case of activation of transcription by 17-E2 through ER, the pool of these co-
activators is mobilized predominantly by ER at the expense of NF-B (Ansari & Gandy, 
2007).  
Therefore, estrogen/ER complex allows developing multiple physiological responses 
following hormonal stimulation by different signaling pathways and inter-connections with 
different trans factors and cis elements at the DNA level of target cells. 
2.3.3 Non genomic signaling pathway 
The non-genomic effects are defined as any action that does not involve transcriptional 
activity resulting from direct or indirect interaction of a nuclear receptor with the regulatory 
sequences of hormone-regulated genes. These effects are very rapid (in the order of several 
seconds to several minutes), incompatible with gene activation or protein synthesis. The 
effects of non-genomic estrogen receptors are often linked to signaling pathways that 
involve G protein-coupled receptors, ion channels or receptors linked to enzymes. 17-E2 
could modulate intracellular calcium or cAMP production and activate MAPK/ERK, PLC, 
PKA, or that of PI3K signaling pathways (Marino et al., 2002) (Fig 2). All these effects are not 
modified by inhibitors of transcription (actinomycin D) or translation (cycloheximide) (Losel 
& Wehling, 2003), confirming that they do not depend on a genomic action. In 1998, Beyer 
and Raab, by coupling 17-E2 to BSA (Bovine Serum Albumin), thereby preventing it from 
crossing the plasma membrane, observed that 17-E2 modulates intracellular calcium. Thus,  
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Fig. 2. Different pathways involved in estrogen receptors (ER) signaling. 
These different pathways occur in estrogen sensitive cells including ERE-dependent genomic, ERE-
independent genomic (via Sp1, AP-1 and NF-B) and membrane associated ER/G protein mechanisms. 
NF-B pathway is the only inhibitory mechanism. In articular chondrocytes ER66 homodimer 
complex binds predominantly Sp1 proteins to activate GC-box mediated trans activation of target genes 
such as Uridine diphospho-glucose deshydrogenase (UDPGD) and type II collagen (type II Col). Other 
mechanisms mediated by ER46 , ER, ER and ER homo- and/or  heterodimer and finally 
membrane associated ER /protein G need to be elucidated in articular chondrocytes. Note that 17-E2 
production from androgens like testosterone takes place via aromatase (CYP19) locally (intracrine effect) 
or in other cells (paracrine or endocrine effects). Adc, Adenylate cyclase; AP-1, Activating Protein-1; 
ERK, Extracellular signal Regulated Kinase; ERE, Estrogen Responsive Element; G, G protein; Hsp-90; 
Heat-shock protein 90; MAPK, Mitogen-Activated Protein Kinase; NF-B, Nuclear Factor-B; PI3K, 
Phosphatidyl Inositol 3-Kinase; PKA, Protein Kinase A; PLC, Phospholipase C; SERM, Selective 
Estrogen Receptor Modulator; Sp1, Specific Protein 1.  
they confirm that this action is induced by a membrane ER. The existence of membrane 
estrogen receptor was discovered in the late 1970s in endometrial cells (Pietras & Szego, 1977). 
Various studies tempted to show that these membrane receptors are structurally similar to the 
classical cytoplasmic ER and that the  and  forms are represented (Chambliss & Shaul, 2002; 
Pappas et al., 1995; Razandi et al., 1999). More recently, a novel isoform of ER was 
highlighted: ER36. This 36 kDa protein lacks the trans activation domains AF-1 and AF-2 and 
has a DBD and a partial LBD, suggesting a membrane localization for this isoform (Wang et 
al., 2006). Also, estrogen binding sites localized at the membrane and the cytoplasm were 
detected in MCF-7 (Harrington et al., 2006). Since ER does not have a transmembrane domain, 
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it appears that palmitoylation of the classical form of the receptor is necessary for its 
membrane addressing (Acconcia et al., 2005; Ellmann et al., 2009). In addition, it has been 
demonstrated that ER could be anchored to the plasma membrane through interactions with 
many membrane proteins such as caveolin 1 and 2, striatine or with adapter proteins like Shc 
and p130 Cas (Crk -associated substrate) (Cheskis et al., 2007). 
2.3.4 Ligand-independent signaling pathway 
In absence of 17-E2, ER can be activated by phosphorylation via protein kinases A or C by 
extracellular signals like growth factors or cytokines, neurotransmitters, or by cell cycle 
regulators (Le Goff et al., 1994). Epidermal growth factor (EGF) mimics the effects of 17-E2 
in the mouse uterus. Similarly, insulin, insulin-like growth factor-I (IGF-I), dopamine or 
transforming growth factor- (TGF-) may activate ER. The main targets of these growth 
factors are the many serine residues present in the AF-1 domain of ER particularly Ser118 
and Ser167 (Nilsson et al., 2001).  
In summary, estrogens are involved in many signaling pathways, allowing fine control of 
cell and tissue functions.  
3. Estrogen involvement in osteoarthritis 
3.1 Epidemiological observations and clinical data 
OA is a worldwide public health problem which may affect different sites of the skeleton. In 
the Western world, at least 10% of the population present OA symptoms and 80% of the 
population will be potentially affected after the age of 70 years.  Knee OA represents one of 
the major causes of morbidity and disability in relation to the worsening of quality of life. 
Pathogenesis of knee OA involves multiple factors including gender, weight, and genetics. 
Association between OA and estrogen deficiency during menopause has been firstly evoked 
by Cecil & Archer in 1925 following clinical observation.  
The hypothesis that estrogen deficiency may promote the development of OA has then 
been relied on the results of observational epidemiological studies. It is known that the 
frequency of knee OA is higher in women than in men; it is worsened after menopause and 
is lower in women receiving hormone replacement therapy (HRT) (Oliveria et al., 1995; 
Wilson et al., 1990). Although contradictions exist, some studies have shown that 
hysterectomy may also be associated with OA suggesting the potential role of estrogens to 
prevent these age-related diseases (Inoue et al., 1995; Spector et al., 1988; Spector et al., 1991). 
In addition, women with metastatic breast cancer when treated with aromatase inhibitors 
develop joint pains and cessation of aromatase inhibitors therapy resolved this joint pain 
(Burstein & Winer, 2007; Crew et al., 2007); aromatase inhibitors are widely used as adjuvant 
therapy in postmenopausal women with ER positive breast cancer (for review see Moslemi 
& Seralini, 2005). Moreover, an association of estrogen receptor (ER and ER) 
polymorphisms has been found in patients with OA compared to unaffected subjects. All 
these data suggest a protective role of estrogen and HRT on OA through functional isoforms 
of ER. Such a protective effect of estrogen on the development of OA may suggest two 
potential mechanisms: a direct effect on cartilage and an indirect effect through 
modifications of sub-chondral bone remodelling. Nevertheless, some clinical studies based 
on symptomatic parameters failed to report any effect of HRT on cartilage metabolism, 
that’s why further studies are required to clearly demonstrate beneficial effects of estrogens 
on molecular regulations of articular cartilage homeostasis. 
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3.2 Biological in vivo and in vitro studies 
In vivo animal studies indicate that estrogens may have a protective effect against OA, 
reversing or reducing the cartilage degradation in ovariectomized mice, rats, sheeps and 
monkeys (Cuzzocrea et al., 2003; Ham et al., 2002; Høegh-Andersen et al., 2004; Oestergaard 
et al., 2006). However, the way by which estrogens act to prevent the pathogenesis of OA in 
these models remains unclear. It is supposed that estrogens prevent cartilage degradation by 
increasing production of growth factors such as insulin growth factor-I (IGF-I) and 
suppressing pro-inflammatory cytokines expression such as interleukin-6 (IL-6). A few data 
exist about the role of estrogen in regulating the synthesis of matrix compounds. In vivo, 
17-E2 prevents the degradation of collagen type II in the women treated with HRT 
(Mouritzen et al., 2003) but in vitro, it does not seem capable of modulating neosynthesis nor 
secretion of type II collagen in articular chondrocytes in primary culture (Ab-Rahim et al., 
2008; Claassen et al., 2006). The measurement of serum C-terminal telopeptide of type II 
collagen (CTX-II) in bovine articular cartilage explants has determined that 17-E2 
significantly protected the cartilage degradation induced by tumor necrosis factor- (TNF-) 
and oncostatin M (Oestergaard et al., 2006). In similar ex vivo experiments, 17-E2 can 
increase glycosaminoglycan (GAG) content of articular explants (Englert et al., 2006). 
Finally, the double invalidation of ER and ER gene receptors (double knock-out ER -/-, 
ER -/-) in mice aged of 6 months increases the number and size of osteophytes as well as a 
thinning of the sub-chondral plate, without changing the cartilage degradation (Sniekers et 
al., 2009). We demonstrated recently that 17-E2 (the most potent among all estrogens) at 
physiologic doses, and ER66 (wild type receptor) but not ER46 (AF-1 deleted receptor) 
could up-regulate at both mRNA and protein levels UDP-glucose dehydrogenase (UDPGD) 
in primary cultured articular chondrocytes via specific protein 1 (Sp1) binding sites (Maneix 
et al., 2008). This enzyme is responsible of UDP-glucuronate synthesis which is the main 
component of GAG chains polymerization in cartilage: it plays an essential role in the 
elongation of GAG chains and their attachment to the axial protein of proteoglycans (PGs). 
Its decarboxylation provides UDP xylose, which serves to anchor chains of chondroitin 
sulfate (CS), dermatan sulfate (DS) and heparan sulphate (HS). Moreover, we also 
established that 17-E2 increases the gene expression of type II collagen (COL2A1), the main 
collagen of hyaline cartilage, via trans activation domains AF-1 of ER66 in coordination 
with the transcription factors Sp1, Sp3, p300 and Soxs (Maneix et al, 2010). It would thus be 
a genomic mechanism ERE-independent. Finally, our preliminary results also showed that 
phytoestrogens such as apigenin and genistein could up-regulate the expression of UDPGD 
(unpublished data).  
Overall, these data indicate that estrogen/phytoestrogens and their receptors can be 
considered as potent regulators of chondrocyte homeostasis and are pro-anabolic for 
extracellular matrix synthesis. This may have potential applications in the tissue engineering 
of articular cartilage and offer new perspectives to prevent and/or to treat OA. 
4. Mechanisms of estrogen action in OA 
4.1 Effects on growth factors and cytokines 
17-E2 can firstly interact with pathways affecting the synthesis and secretion of the key 
growth factors involved in the regulation of cartilage metabolism. So, TGF- expression in the 
iliac crest chondrocytes is influenced by 17-E2 in a biphasic manner: low concentrations of 
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17-E2 increase TGF- expression whereas supra-physiologic doses decrease strongly its 
expression (Saggese et al., 1993). The concept of dose-dependence is confirmed by the majority 
of the studies on 17-E in the articular cartilage where physiological doses of the hormone 
show to be protective when considering the structural integrity of tissue while supra-
physiologic concentrations are often deleterious (Richette et al., 2003) (Fig. 3). Experiments on 
chondrocytes from ovariectomized monkeys treated with 17-E showed that this hormone 
increases concomitantly the expression of the binding protein of IGF-I (IGFBP-2) and synthesis 
of PG (Richmond et al., 2000). In addition, the synovial fluid of these animals contains IGF-I 
twice more than untreated animals. Thereafter, it was shown that estrogen deficiency increases 
the sensitivity of cell response to certain pro-inflammatory cytokines through an increase in 
the number of receptors or cytokine cofactors amplifying consequently the effects of catabolic 
cytokines in these cells. Estrogen treatment in ovariectomized animals significantly reduced 
the production and secretion of pro-inflammatory cytokines in articular chondrocytes. This 
anti-inflammatory effect of 17-E2 was highlighted by Le Bail et al. (2001) who showed that the 
localized production of 17-E2 by synovial cells has inhibited the IL-6 secretion by articular 
chondrocytes. In addition, 17-E2 can also reduce production of pro-inflammatory 
prostaglandins through a decrease in the mRNA steady-state levels of cyclooxygenase-2 
(COX-2) in bovine articular chondrocytes (Morisset et al., 1998). 
4.2 Metalloproteinases (MMPs) expression and activity 
The majority of the beneficial effects of 17-E2 in articular chondrocytes is focused on the 
inhibition of catabolic pathways. Thus, Lee et al. (2003) found that 17-E2 decreases the 
secretion of the metalloproteinase MMP-1 in human osteoarthritic articular chondrocytes. In 
addition, 17-E2 can antagonize the degradation of PGs and the expression and activity of 
MMP-1, MMP-3 and MMP-13 enzymes induced by IL-1 in rabbit articular chondrocytes 
(Richette et al., 2004). Especially, the effects of 17-E2 on the expression of MMP-13 seem to be 
transmitted through the indirect binding of ER66 at an AP-1 site in the promoter of MMP-13 
gene (Lu et al., 2006). Like the mode of action of 17-E2 on the expression levels of TGF-, the 
effects of the hormone on the expression of MMPs and their inhibitors TIMPs (tissue inhibitors 
of MMPs) appear to be dose-dependent. Low doses of 17-E2 decreased MMP-1/TIMP-1 and 
MMP-3/TIMP-1 ratios while higher concentrations have the opposite effect (Song et al., 2003). 
4.3 Anti-oxidant effects 
The generation of reactive oxygen species (ROS) contributes actively to the cartilage ECM 
degradation in OA, in particular by inducing a decrease in the synthesis of PGs. However, 
due to the structure of their phenol nuclei, 17-E2 and its metabolites have anti-oxidant 
features (Liehr & Roy, 1998) that protect the cartilage degradation induced by ROS 
(Claassen et al., 2005). It is now established that 17-E2 is a modulator of the redox status of 
chondrocytes. 
During the arthritic process, overproduction of nitric oxide (NO) is a consequence of the 
action of proinflammatory cytokines such as IL-1 or TNF- that promote the activation of 
inducible nitric oxide synthase (iNOS) in OA chondrocytes. The iNOS gene is under the 
control of an estrogen-dependent promoter. Indeed, estrogen deficiency activates 
transcription of this promoter while a replacement therapy by 17-E2 inhibits it in 
ovariectomized mice (Cuzzocrea et al., 2003). 17-E2 can counteract the deleterious effects 
induced by IL-1 in rabbit articular chondrocytes by reducing the binding capacity of NF-B  
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Fig. 3. Role of 17-E2 and estrogen receptor ER /ER on joint cartilage homeostasis. 
Col II, type II collagen; IGF-I, Insulin-like Growth Factor-I; IL, Interleukin; iNOS, Inducible Nitrogen 
Oxide Synthase; MMPs, Metalloproteinases; PGs, Proteoglycans; ROS, Reactive Oxygen Species; SERM, 
Selective Estrogen Receptor Modulators; TIMPs, Tissue Inhibitors MMPs; TGF-, Transforming Growth 
Factor-; TNF-, Tumor Necrosis Factor-; UDPGD, Uridine Diphospho-Glucose Dehydrogenase. The 
roles of SERM and phytoestrogens need to be clarified. 
in the promoter of iNOS gene resulting in inhibition of nuclear translocation of this factor 
(Richette et al., 2007). This results in an inhibition of iNOS gene transcription and a 
subsequent reduction in NO production by chondrocytes. 
4.4 Matrix components turn-over 
To better understand the physiopathology of articular cartilage in osteoarthritis, Høegh-
Andersen et al. (2004) have validated an experimental model of ovariectomized rats with 
modification in cartilage structure representative of in vivo pathological changes observed in 
early human osteoarthritis. In animals aged from 5 to 7 months, estrogen deficiency 
increases the erosion of the articular surface and accelerates the renewal of matrix 
molecules. This animal model also showed that the effectiveness of HRT in the prevention of 
cartilage loss is increased when estrogen is administered to the animal from its operation 
and not after a period of 3 weeks (Oestergaard et al. 2006). These works need to be 
compared with the many epidemiological data which showed that the benefits of HRT are 
strengthened when patients are treated at the first signs of menopause and continued their 
treatment over a period exceeding 5 years. The importance of prevention in the treatment of 
damaged cartilage appears essential.  
4.5 Sub-chondral bone regulation 
Within the joint, cartilage is not the only target tissue for estrogens. 17-E2 also controls the 
renewal of the sub-chondral bone by maintaining a balance between the two players in bone 
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remodeling: osteoblasts that synthesize bone matrix and osteoclasts that are responsible for 
the resorption (bone loss) of existing bone. Estrogens inhibit osteoclasts activation and are 
therefore considered as inhibitors of bone resorption. The predominant mechanism that 
appears to be involved is the inhibition of IL-6 synthesis, the main cytokine involved in the 
activation of resorption. This inhibition of IL-6 synthesis by estrogens is mediated through 
the modification of NF-B binding on IL-6 gene promoter; there is no direct binding of ER to 
DNA (Ray et al., 1994). Consequently, an increase of bone resorption, generally favoring the 
occurrence of osteoporosis, is frequently seen in women after menopause which is related to 
the decrease of circulating estrogen levels during this period (Reginster et al., 2003). In this 
context, HRT could effectively prevent postmenopausal osteoporosis. 
Paradoxically, the frequency of OA and osteoporosis in postmenopausal women are most 
often inversely correlated, as reflected in the levels of osteocalcin, a marker of bone 
turnover, which are generally lower among women with OA than women without OA (for 
review: Dequeker et al., 2003). Patients suffering from OA of the knee are generally less 
subjected to bone loss. The increase in bone mass is a risk factor for incidence and 
development of knee and hip osteoarthritis. It was suggested that an increase in bone 
density in the area of the sub-chondral bone may induce bone stiffness and accelerate 
cartilage destruction. Thus, high bone density is associated with an increase of OA 
prevalence of the hip, hand and knee in postmenopausal women. However, high bone 
density increases risk of knee OA but protects against the progression of the disease once it 
is established. Therefore, bone loss in people with OA which is already established 
accelerates the progression of the disease. Indeed, Jacobsen et al. (2007) showed that the 
reduction of intra-articular space in the hip was correlated with the decrease in mineral 
density of sub-chondral bone in postmenopausal women. It was suggested that the 
alteration of bone structure can cause changes in the load distribution within the joint and 
promote the development of OA (Sniekers et al. 2008). In this case, the favorable effect of 
estrogen on cartilage may be due in part to the anti-resorption effect of 17-E2 on bone. 
5. Phytoestrogen and Selective Estrogen Receptor Modulators (SERM) 
During the second half of the 20th century, HRT has been repeatedly promoted as the only 
pharmacological approach allowing a global prevention of all disorders related to or 
potentiated by estrogen deprivation. Recently, the risk/benefit profile of HRT has been 
severely challenged because of apparent increased risks of invasive breast cancer, coronary 
heart disease events, stroke and pulmonary embolism among treated women. These new 
findings imply a careful reassessment of the current evidence justifying the prescription of 
HRT for the prevention of the management of chronic disorders.  The many contradictions 
recorded concerning benefit/risk effects of HRT are often related to differences in 
methodology and criteria used in measuring the effects of estrogen therapy in clinical 
studies. Indeed, analysis based strictly on symptomatic parameters showed that HRT had 
no effect or even adverse effects on the progression of OA (Von Muhlen et al., 2002). 
Conversely, more advanced techniques of magnetic resonance imaging showed that 
recipients of long term HRT (5 years or more) had a volume of articular cartilage largest in 
the knee than women having never taken any treatments (Wluka et al., 2001). As to the 
evolution of medical imaging techniques and advances in the diagnosis of OA, it appears 
that estrogens have a strong potential for preventing disease and preserving the structural 
integrity of the articulation among postmenopausal women. Thus, recent clinical trials of 
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consortium “Women's Health Initiative” showed that women treated with equine estrogens 
over a period of 7 years had 17% lower risk to undergo a hip replacement compared to 
control group (Cirillo et al., 2006). Finally, an in vivo study performed on 180 ovariectomized 
monkeys for 3 years found that HRT reduced the severity of arthritic lesions, through 
attenuation of the PGs loss and reducing the number of osteophytes in these animals (Ham 
et al., 2002). Given its chondroprotective potential, it would seem that HRT is capable of 
modulating chondrocyte metabolism. Studies have also shown that SERM and 
phytoestrogens may have beneficial effect on cartilage metabolism and to alleviate OA 
symptoms (Arjmandi et al, 2004; Bassleer et al., 1996; Guiducci et al., 2005; Tsai et al., 1992). 
It has been shown that when administered at a clinically relevant dose in young male rats, 
tamoxifen causes persistent retardation of longitudinal and cortical radial bone growth 
through systemic suppression of IGF-I production and local effects on the growth plate 
cartilage; it increases in chondrocytes proliferation/apoptosis and decreases the number of 
hypertophic chondrocytes (Karimian et al., 2008). Similarly, raloxifen could act as estrogen 
agonist on the growth plate of ovariectomized immature rabbits, accelerating growth plate 
senescence and thus hastening epiphyseal fusion (Nilsson et al, 2003). 
Besides estrogens, natural molecules such as phytoestrogens (estrogen-like compounds in 
plants) sharing structural and functional homologies with endogenous estrogens, could also 
act (even thought at micromolar concentrations) as agonists and/or antagonists in hormone-
sensitive target cells. Scientists are now interested in the tissue-selective activities of 
phytoestrogens considering anti-estrogenic effects in reproductive tissue that could help to 
reduce the risk of hormone-associated cancers (breast, uterine, ovarian, and prostate), while 
estrogenic effects on bone and cardiovascular system for instance could favor the 
maintenance of bone density and protect against atherosclerosis respectively. Moreover, it 
has been suggested that the consumption of dietary phytoestrogens (soja isoflavones, 
lignans, etc.) may have beneficial effects on bone health at all stages of life. That’s why 
phytoestrogens have aroused much interest as potential substitutes in HRT of 
postmenopausal women, but they require much further investigation regarding their 
mechanism of action and their safety. Like estrogens, phytoestrogens may act via genomic 
and non genomic pathways. The most relevant molecular actions of phytoestrogens are 
those mediated by ERs. They may act on protein tyrosine kinase, MAP kinase, 
topoisomerase II and at all stages of cell cycle and apoptosis. They can also change the 
response to growth factors and cytokines. Genistein up to 100 M reduces the production of 
lipopolysaccharide (LPS)-stimulated pro-inflammatory molecules (COX-2, NO) but not that 
of COX-1 responsible of releasing prostaglandins in normal human chondrocytes 
(Hooshmand et al., 2007). When tested on human chondrocytes and chondrocytic cell line 
CHON-002, bavachin, a flavonid phytoestrogen isolated from Psoralea corylifolia, potentially 
protected cartilage from inflammation-mediated damage in joints of OA through decreasing 
IL-1beta-induced activation of IKK-IB alpha-NF-B signaling pathway (Cheng et al., 2010). 
Formononetin, a phytoestrogen isolated from Astragalus membranaceus showed to have 
biphasic positive effects on human normal osteoblasts and OA sub-chondral osteoblasts by 
modifying their biological synthetic capacities (Huh et al., 2010). Using female bovine 
articular chondrocytes, it has been demonstrated that the stimulating effect of insulin on 
GAGs sulfate incorporation was enhanced significantly after preincubation of cells with 10-11 
-10-5 M daidzein or 10-9 -10-5 M genistein but not by 17-E2 (Claassen et al., 2008). More 
recently, xanthohumol, a prenylflavonoid extracted from hop, showed to prevent 
hyaluronan overproduction as well as PG and collagen loss in bovine chondrocytes; 
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hyluronan overproduction is considered as an early reaction in OA followed by PG loss and 
collagen degradation (Stracke et al., 2001).  However, additional research is critical to 
determine how phytoestrogens act on cartilage cells to obtain a more complete 
understanding of the effects. 
6. Conclusion 
From epidemiological, clinical, in vivo and in vitro studies, a huge amount of data consistent 
with the fact that estrogens and their receptors can now be considered among the main 
players involved in the chondrocyte homeostasis and participate in cartilage protection from 
degradation and erosion occurring during menopause. Indeed, once ligand/ER complex is 
formed, estrogens such as 17-E2 could act with ER to induce or to inhibit trans activation of 
target genes of chondrocytes, the predominant cells of articular cartilage allowing 
expression of the specific chondrogenic markers such as UDPGD, PGs, type II collagen or 
inhibition of catabolic markers such as metalloproteinases and interleukins. There are 
different pathways by which estrogen and ER may interact with target genes in 
chondrocytes but it seems that Sp1 mediated trans activation being preferentially used in 
this cell type. In this mechanism ER needs AF-1 sequence (ligand-independent trans 
activation domain) to exert its action on GC boxes via Sp1 in target genes. In addition, some 
molecules sharing structural and functional features with estrogens like SERM and 
phytoestrogens can mimic estrogenic action and are therefore useful to repair cartilage 
erosion or might contribute at least to protect premenopausal joint cartilage and to maintain 
its homeostasis in a prevention strategy but these molecules need further investigation and 
deserves more attention from the scientific community to prove their safety and efficacy. 
7. Key points 
Osteoarthritis, cartilage, chondrocytes, estrogens, phytoestrogens, selective estrogen 
receptor modulators, hormone replacement therapy, menopause. 
8. References 
Ab-Rahim, S., Selvaratnam, L. & Kamarul, T. (2008). The effect of TGF-beta1 and beta-
estradiol on glycosaminoglycan and type II collagen distribution in articular 
chondrocyte cultures. Cell Biol. Int., Vol. 32, No. 7, (Jul 2008), pp. (841-847)  
Acconcia, F., Ascenzi, P., Bocedi, A., Spisni, E., Tomasi, V., Trentalance, A., Visca, P. & 
Marino, M. (2005). Palmitoylation-dependent estrogen receptor alpha membrane 
localization: regulation by 17beta-estradiol. Mol. Biol. Cell, Vol. 16, No. 1, (Jan 2005), 
pp. (231-237)  
Ansari, R.A. & Gandy, J. (2007). Determining the transrepression activity of xenoestrogen on 
nuclear factor-kappa B in Cos-1 cells by estrogen receptor-alpha. Int. J. Toxicol., Vol. 
26, No. 5, (Sep-Oct 2007), pp. (441-449)  
Antonicelli R, Olivieri F, Morichi V, Urbani E, Mais V. (2008). Prevention of cardiovascular 
events in early menopause: a possible role for hormone replacement therapy. Int J 
Cardiol., Vol. 130, No. 2, (Nov 2008),  pp. (140-146), Review 
Arjmandi, B.H., Khalil, D.A., Lucas, E.A., Smith, B.J., Sinichi, N., Hodges, S.B., Juma, S., 
Munson, M.E., Payton, M.E., Tivis, R.D. & Svanborg, A. (2004). Soy protein may 
www.intechopen.com
 
Challenges in Rheumatology 54
alleviate osteoarthritis sympthoms. Phytomedicine, Vol. 11, No. 7-8, (Nov 2004), pp. 
(567-575) 
Ascenzi, P., Bocedi, A. & Marino, M. (2006). Structure-function relationship of estrogen 
receptor alpha and beta: impact on human health. Mol. Aspects Med., Vol. 27, No. 4, 
(Aug 2006), pp. (299-402), Review 
Barrailler, P., Chinestra, P., Bayard, F. & Faye, J.C. (1999). Alternative initiation of translation 
accounts for a 67/45 kDa dimorphism of the human estrogen receptor ERalpha. 
Biochem. Biophys. Res. Commun., Vol. 257, No. 1, (Apr 1999), pp. (84-88)  
 Bassleer, C.T., Franchimont, P.P., Henrotin, Y.E., Franshimount, N.M., Geenen, V.G. & 
Reginster, J.Y. (1996). Effects of ipriflavone and its matabolites on human articular 
chondrocytes cultivated in clusters. Osteoarthritis Cartilage, Vol. 4, No. 1, (Mar 1996), 
pp. (1-8) 
Bergink, A.P., Van Meurs, J.B., Loughlin, J., Arp, P.P., Fang, Y., Hofman, A., Van Leeuwen, 
J.P., Van Duijn, C.M., Uitterlinden, A.G. & Pols, H.A. (2003). Estrogen receptor 
alpha gene haplotype is associated with radiographic osteoarthritis of the knee in 
elderly men and women. Arthritis Rheum., Vol.48, No. 7, (Jul 2003), pp. (1913-1922) 
Beyer, C. & Raab, H. (1998). Nongenomic effects of oestrogen: embryonic mouse midbrain 
neurones respond with a rapid release of calcium from intracellular stores. Eur. J. 
Neurosci., Vol. 10, No. 1 (Jan 1998), pp. (255-262)  
Calleja-Agius, J. & Brincat, M.P. (2009). Effects of hormone replacement therapy on 
connective tissue: why is this important? Best Practice & Research Clinical Obstetrics 
and Gynaecology, Vol. 23, No. 1, (Feb 2009), pp. (121–27) 
Candore, G., Balistreri, CR., Grimaldi, M.P., Vasto, S., Listì, F., Chiappelli, M., Licastro, F., 
Lio, D. & Caruso, C. (2006). Age-related inflammatory diseases: role of genetics and 
gender in the pathophysiology of Alzheimer's disease. Ann N Y Acad Sci, Vol. 1089, 
(Nov 2006), pp. (472-486), Review 
Cecil, R.L. & Archer, B.H. (1925). Arthritis of the menopause, JAMA, Vol. 84 pp. (75–79) 
Chagin, A.S., Karimian, E., Zaman, F., Takigawa, M., Chrysis, D., Sävendahl, L. (2007). 
Tamoxifen induces permanent growth arrest through selective induction of 
apoptosis in growth plate chondrocytes in cultured rat metatarsal bone. Bone, Vol. 
40, No. 5, (May 2007), pp. (1415-1424) 
Cheng, C.C., Chen, Y.H., Chang, W.L., Yang, S.P., Chang, D.M., Lai, J.H. & Ho, L.J. (2010). 
Phytoestrogen bavachin mediates anti-inflammation targeting Ikappa B kinase-I 
kappaB alpha-NF-kappaB signaling pathway in chondrocytes in vitro. Eur J 
Pharmacol. Vol. 636, No. 1-3,  (Jun 2010), pp. (181-188)   
Chambliss, K.L. & Shaul, P.W. (2002). Estrogen modulation of endothelial nitric oxide 
synthase. Endocr. Rev., Vol.23, No. 5, (Oct 2002), pp. (665-686), Review 
Cheskis, B.J., Greger, J.G., Nagpal,  S. & Freedman, L.P. (2007). Signaling by estrogens. J. Cell 
Physiol., Vol. 213, No. 3, (Dec 2007), pp. (610-617), Review 
Cirillo, D.J., Wallace; R.B., Wu; L. & Yood; R.A. (2006). Effect of hormone therapy on risk of 
hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum., 
Vol. 54, No. 10, (Oct 2006), pp. (3194-3204) 
Claassen, H., Briese, V., Manapov, F., Nebe, B., Schünke, M. & Kurz, B. (2008). The 
phytoestrogens daidzein and genistein enhance the insulin-stimulated sulfate 
www.intechopen.com
 
Estrogens Involvement in the Physiopathology of Articular Cartilage 55 
uptake in articular chondrocytes. Cell Tissue Res., Vol. 333, No. 1, (Jul 2008), pp. (71-
79) 
Claassen, H., Schunke, M. & Kurz, B. (2005). Estradiol protects cultured articular 
chondrocytes from oxygen-radical-induced damage. Cell Tissue Res., Vol. 319, No. 
3, (Mar 2005), pp. (439-445)  
Claassen, H., Schluter, M., Schunke, M. & Kurz, B. (2006). Influence of 17beta-estradiol and 
insulin on type II collagen and protein synthesis of articular chondrocytes. Bone, 
Vol. 39, No. 2, (Aug 2006), pp. (310-317) 
Cotter, A. & Cashman, K.D. (2003). Genistein appears to prevent postmenopausal bone loss 
as effectively as hormone replacement therapy. Nutr Rev., Vol. 61, No. 10, (Oct 
2003), pp. (346-351) 
Cuzzocrea, S., Mazzon, E., Dugo, L., Genovese, T., Di Paola, R., Ruggeri, Z., Vegeto, E., 
Caputi, A.P., Van De Loo, F.A., Puzzolo, D. & Maggi, A. (2003). Inducible nitric 
oxide synthase mediates bone loss in ovariectomized mice. Endocrinology, Vol. 144, 
No. 3, (Mar 2003), pp. (1098-1107)  
Dequeker, J., Aerssens, J. & Luyten, F.P. (2003). Osteoarthritis and osteoporosis: clinical and 
research evidence of inverse relationship. Aging Clin. Exp. Res., Vol. 15, No. 5, (Oct 
2003), pp. (426-439), Review  
Dodin, S., Blanchet, C. & Marc, I. (2003). Phytoestrogens in menopausal women: a review of 
recent findings. Med Sci (Paris), Vol. 19, No. 10, (Oct 2003), pp. (1030-1037), Review 
(French) 
Duan, R., Ginsburg, E. & Vonderhaar, B.K. (2008). Estrogen stimulates transcription from 
the human prolactin distal promoter through AP1 and estrogen responsive 
elements in T47D human breast cancer cells. Mol. Cell Endocrinol., Vol. 281, No. 1-2, 
(Jan 2008), pp. (9-18)  
Elders, M.J. (2000). The increasing impact of arthritis on public health.  J Rheumatol Suppl, 
Vol. 6, (Oct 2000), pp. (6-8)  
Ellmann, S., Sticht, H., Thiel, F., Beckmann, M.W., Strick, R. & Strissel, P.L. (2009). Estrogen 
and progesterone receptors: from molecular structures to clinical targets. Cell Mol. 
Life Sci., Vol. 66, No. 15, (Aug 2009), pp.  (2405-2426)  
Englert, C., Blunk, T., Fierlbeck, J., Kaiser, J., Stosiek W., Angele, P., Hammer, J. & Straub, 
R.H. (2006). Steroid hormones strongly support bovine articular cartilage 
integration in the absence of interleukin-1beta. Arthritis Rheum., Vol. 54, No. 12, 
(Dec 2006), pp. ( 3890-3897)  
Felson, D.T. & Nevitt, M.C. (1998). The effect of estrogen on osteoarthritis. Curr Opin 
Rheumatol, Vol. 10, No. 3, (May 1998), pp. (269-272)  
Flouriot, G., Brand, H., Denger, S., Métivier, R., Kos, M., Reid, G., Sonntag-Buck, V. & 
Gannon, F. (2000). Identification of a new isoform of the human estrogen receptor-
alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress 
hER-alpha activation function 1. EMBO J., Vol. 19, No. 17, (Sep 2000), pp. (4688-
4700)  
Flouriot, G., Griffin, C., Kenealy, M., Sonntag-Buck, V. & Gannon, F. (1998). Differentially 
expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are 
generated by alternative splicing and promoter usage. Mol. Endocrinol., Vol. 12, No. 
12, (Dec 1998), pp. (1939-1954)  
www.intechopen.com
 
Challenges in Rheumatology 56
Galien, R. & Garcia, T. (1997). Estrogen receptor impairs interleukin-6 expression by 
preventing protein binding on the NF-kappaB site. Nucleic Acids Res, Vol. 25, No. 
12, (Jun 1997), pp. (2424-2429) 
Germain, P., Staels, B., Dacquet, C., Spedding, M. & Laudet, V. (2006). Overview of 
nomenclature of nuclear receptors. Pharmacol. Rev., Vol. 58, No. 4, (Dec 2006), pp. 
(685-704) 
Gottlicher, M., Heck, S. & Herrlich, P. (1998). Transcriptional cross-talk, the second mode of 
steroid hormone receptor action. J. Mol. Med., Vol. 76, No. 7, (Jun 1998), pp.  (480-
489)  
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.M., Argos, P. & Chambon, P. (1986). 
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. 
Nature, Vol. 320, No. 6058, (Mar 1986), pp. (134-139)  
Guiducci, S., Del Rosso, A., Cinelli, M., Margheri, F., D'Alessio, S., Fibbi, G., Matucci Cerinic, 
M., Del Rosso, M. (2005). Rheumatoid synovial fibroblasts constitutively express 
the fibronolytic pattern of invasive tumor-like cells. Clin Exp Rheumatol., Vol. 23, 
No. 3, (May 2005), pp. (364-372)   
Hall, J.M., Couse, J.F. & Korach, K.S. (2001). The multifaceted mechanisms of estradiol and 
estrogen receptor signaling. J. Biol. Chem., Vol. 276, No. 40, (Oct 2001), pp. (36869-
36872)  
Hall, J.M. & McDonnell, D.P. (1999). The estrogen receptor beta-isoform (ERbeta) of the 
human estrogen receptor modulates ERalpha transcriptional activity and is a key 
regulator of the cellular response to estrogens and antiestrogens. Endocrinology, Vol. 
140, No. 12, (Dec 1999), pp. (5566-5578)  
Ham, K.D., Loeser, R.F., Lindgren, B.R. & Carlson, C.S. (2002). Effects of long-term estrogen 
replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis 
Rheum., Vol. 46, No. 7, (Jul 2002), pp. (1956-1964)  
Harrington, W.R., Kim, S.H., Funk, C.C., Madak-Erdogan, Z., Schiff, R., Katzenellenbogen, 
J.A. & Katzenellenbogen, B.S. (2006). Estrogen dendrimer conjugates that 
preferentially activate extranuclear, nongenomic versus genomic pathways of 
estrogen action. Mol. Endocrinol., Vol. 20, No. 3, (Mar 2006), pp. (491-502)  
He, S., Sun, J.M., Li, L. & Davie, J.R. (2005). Differential intranuclear organization of 
transcription factors Sp1 and Sp3. Mol. Biol. Cell, Vol. 16, No. 9, (Sep 2005), pp. 
(4073-4083)  
Høegh-Andersen, P., Tanko, L.B., Andersen, T.L., Lundberg, C.V., Mo, J.A., Heegaard, A.M., 
Delaisse, J.M. & Christgau, S. (2004). Ovariectomized rats as a model of 
postmenopausal osteoarthritis: validation and application. Arthritis Res. Ther., Vol. 
6, No. 2, (Feb 2004), pp. (R169-R180)  
Hooshmand, S., Soung do, Y., Lucas, E.A., Madihally, SV., Levenson, C.W. & Arjmandi, B.H. 
(2007). Genistein reduces the production of proinflammatory molecules in human 
chondrocyes. J Nut Biochem., Vol. 18, No. 9, (Sep 2007), pp. (609-614)  
Huh, J.E., Seo, D.M., Baek, Y.H., Choi, D.Y., Park, D.S. & Lee, J.D. (2010). Biphasic positive 
effect of formononetin on metabolic activity of human normal and osteoarthritic 




Estrogens Involvement in the Physiopathology of Articular Cartilage 57 
Inoue, K., Ushiyama, T., Kim, Y., Shichikawa, K., Nishioka, J., Hukuda, S. (1995). Increased 
rate of hysterectomy in women undergoing surgery for osteoarthritis of the knee. 
Osteoarthritis Cartilage,  Vol. 3, No. 3, (Sep 1995), pp. (205–209) 
Jacobsen, S., Jensen, T.W., Bach-Mortensen, P., Hyldstrup, L. & Sonne-Holm, S. (2007). Low 
bone mineral density is associated with reduced hip joint space width in women: 
results from the Copenhagen Osteoarthritis Study. Menopause, Vol. 14, No. 6, (Nov-
Dec 2007), pp. (1025-1030)  
Jensen, E.V. & DeSombre, E.R. (1973). Estrogen-receptor interaction. Science, Vol. 182, No. 
108, (Oct 1973), pp. (126-134), Review 
Karimian, E, Chagin, AS., Gjerde, J., Heino, T., Lien, EA., Ohlsson, C. & Sävendahl, L. (2008). 
Tamoxifen impairs both longitudinal and cortical bone growth on young male rats.  
J bone Miner Res., Vol. 23, No. 8, (Aug 2008), pp. (1267-1277)  
Khalil, R.A. (2010). Potential approaches to enhance the effects of estrogen on senescent 
blood vessels and postmenopausal cardiovascular disease. Cardiovasc Hematol 
Agents Med Chem., Vol. 8, No. 1, (Jan 2010), pp. (29-46) 
Kim, K., Thu, N., Saville, B. & Safe, S. (2003). Domains of estrogen receptor alpha (ERalpha) 
required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens 
and antiestrogens in breast cancer cells. Mol. Endocrinol., Vol. 17, No. 5, (May 2003), 
pp. (804-817) 
Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S. & Gustafsson, J.A. (1996). Cloning of 
a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A., 
Vol. 93, No. 12, (Jun 1996), pp. (5925-5930)  
Kushner, P.J., Agard, D.A., Greene, G.L., Scanlan, T.S., Shiau, A.K., Uht, R.M. & Webb, P. 
(2000). Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol., Vol. 74, 
No. 5, (Nov 2000), pp. (311-317)  
Le Bail, J., Liagre, B., Vergne, P., Bertin, P., Beneytout, J. & Habrioux, G. (2001). Aromatase in 
synovial cells from postmenopausal women. Steroids, Vol. 66, No. 10, (Oct 2001), 
pp. (749-757)  
Lee, Y.J., Lee, E.B., Kwon, Y.E., Lee, J.J., Cho, W.S., Kim, H.A. & Song, Y.W. (2003). Effect of 
estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and 
MMP-13 and tissue inhibitor of metalloproteinase-1 in osteoarthritis chondrocytes. 
Rheumatol. Int., Vol. 23, No. 6, (Nov 2003), pp. (282-288) 
Le Goff, P., Montano, M.M., Schodin, D.J. & Katzenellenbogen, B.S. (1994). Phosphorylation 
of the human estrogen receptor. Identification of hormone-regulated sites and 
examination of their influence on transcriptional activity. J. Biol. Chem., Vol. 269, 
No. 6, (Feb 1994), pp. (4458-4466)  
Liehr, J.G. & Roy, D. (1998). Pro-oxidant and antioxidant effects of estrogens. Methods Mol. 
Biol., Vol. 108, pp. (425-435) 
Losel, R. & Wehling, M. (2003). Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell 
Biol., Vol. 4, No. 1, (Jan 2003), pp. (46-56), Review 
Lu, T., Achari, Y., Sciore, P. & Hart, D.A. (2006). Estrogen receptor alpha regulates matrix 
metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional 
regulatory site. Biochim. Biophys. Acta, Vol. 1762, No. 8, (Aug 2006), pp. (719-731)  
Maneix, L., Beauchef, G., Servent, A., Wegrowski, Y., Maquart, F.X., Boujrad, N., Flouriot, 
G., Pujol, J.P., Boumediene, K., Galéra, P. & Moslemi, S.  (2008) 17-Estradiol up-
www.intechopen.com
 
Challenges in Rheumatology 58
regulates the expression of a functional UDP-glucose dehydrogenase in articular 
chondrocytes: Comparison with effects of cytokines and growth factors. 
Rheumatology (Oxford), Vol. 47, No. 3, (Mar 2008), pp. (281-288)  
Maneix, L., Boujrad, N., Flouriot, G., Demoor, M., Boumediene, K., Moslemi, S. & Galéra, P. 
(2010). 17┚-estradiol-induced up-regulation of type II collagen expression is 
mediated by ER┙/Sp/SOX9/p300 complex through COL2A1 promoter/first intron 
interactions in differentiated and dedifferentiated articular chondrocytes. World 
Congress on osteoarthritis, OARSI, Brussels, Belgium, September 2010  
Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, 
B., Kastner, P., Mark, M., Chambon, P. & Evans R.M. (1995). The nuclear receptor 
superfamily: the second decade.  Cell, Vol. 83, No. 6, (Dec 1995), pp. (835-839), 
Review 
Marino, M., Acconcia, F., Bresciani, F., Weisz, A. & Trentalance, A. (2002). Distinct 
nongenomic signal transduction pathways controlled by 17beta-estradiol regulate 
DNA synthesis and cyclin D1 gene transcription in HepG2 cells. Mol. Biol. Cell, Vol. 
13, No. 10, (Oct 2002), pp. (3720-3729)  
Matthews, J., Wihlen, B., Tujague, M., Wan, J., Strom, A. & Gustafsson, J.A. (2006). Estrogen 
receptor (ER) beta modulates ERalpha-mediated transcriptional activation by 
altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol. 
Endocrinol., Vol. 20, No. 3, (Mar 2006), pp. (534-543) 
McKenna, N.J., Lanz, R.B. & O'Malley, B.W. (1999). Nuclear receptor coregulators: cellular 
and molecular biology. Endocr. Rev., Vol. 20, No. 3, (Jun 1999), pp. (321-344), 
Review  
Metivier, R., Penot, G., Flouriot, G. & Pakdel, F. (2001). Synergism between ERalpha 
transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator 
protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction 
between the N- and C-terminal domains. Mol. Endocrinol., Vol. 15, No. 11, (Nov 
2001), pp. (1953-1970) 
Morisset, S., Patry, C., Lora, M. & De Brum-Fernandes, A.J. (1998). Regulation of 
cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 
1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J. 
Rheumatol., Vol. 25, No. 6, (Jun 1998), pp. (1146-1153) 
Moslemi, S. & Seralini, S. (2005). Estrogens and breast cancer: Aromatase activity disruption. 
In: Trends in Breast Cancer Research, Editor: Andrew, P. Yao, pp. (101-127), ISBN, 1-
59454-134-5, Nova Science Publishers, Inc., New York 
Mouritzen, U., Christgau, S., Lehmann, H.J., Tanko, L.B. & Christiansen, C. (2003). Cartilage 
turnover assessed with a newly developed assay measuring collagen type II 
degradation products: influence of age, sex, menopause, hormone replacement 
therapy, and body mass index. Ann. Rheum. Dis., Vol. 62, No. 4, (Apr 2003), pp. 
(332-336) 
Nasatzky, E., Schwartz, Z., Soskolne, W.A., Brooks B.P., Dean D.D., Boyan B.D. & Ornoy A. 
(1994). Evidence for receptors specific for 17 beta-estradiol and testosterone in 
chondrocyte cultures. Connect. Tissue Res., Vol. 30, No. 4, pp. (277-294) 
www.intechopen.com
 
Estrogens Involvement in the Physiopathology of Articular Cartilage 59 
Nilsson, O., Falk, J., Ritzén, E.M., Baron, J. & Sävendahl, L. (2003). Raloxifene acts as an 
estrogen agonist on the rabbit growth plate. Endocrinology, Vol. 144, No. 4, (Apr 
2003), pp. (1481-1485)  
Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., 
Pettersson, K., Warner, M. & Gustafsson, J.A. (2001). Mechanisms of estrogen 
action. Physiol Rev., Vol. 81, No. 4, (Oct 2001), pp. (1535-1565) 
Nuclear Receptor Nomenclature Committee (1999). A unified nomenclature system for the 
nuclear receptor superfamily, Cell, Vol. 97, No. 2, (Apr 1999), pp. (161-163)  
Oestergaard, S., Sondergaard, B.C., Hoegh-Andersen, P., Henriksen, K, Qvist, P., 
Christiansen, C., Tanko, L.B. & Karsdal, M.A. (2006). Effects of ovariectomy and 
estrogen therapy on type II collagen degradation and structural integrity of 
articular cartilage in rats: implications of the time of initiation. Arthritis Rheum., Vol. 
54, No. 8, (Aug 2006), pp. (2441-2451)  
Oliveria, SA., Felson, D.T., Reed, J.I., Cirillo, P.A. & Walker, AM. (1995). Incidence of 
symptomatic hand, hip, and knee osteoarthritis among patients in a health 
maintenance organization. Arthritis Rheum., Vol. 38, No. 8, (Aug 1995), pp. (1134-
1141)  
Paech, K., Webb, P., Kuiper, G.G., Nilsson, S., Gustafsson, J., Kushner, P.J. & Scanlan, T.S. 
(1997). Differential ligand activation of estrogen receptors ERalpha and ERbeta at 
AP1 sites. Science, Vol. 277, No. 5331, (Sep 1997), pp. (1508-1510)  
Pappas, T.C., Gametchu, B. & Watson, C.S. (1995). Membrane estrogen receptors identified 
by multiple antibody labeling and impeded-ligand binding. FASEB J., Vol. 9, No. 5, 
(Mar 1995), pp. (404-410)  
Pearce, S.T. & Jordan, V.C. (2004). The biological role of estrogen receptors alpha and beta in 
cancer. Crit. Rev. Oncol. Hematol., Vol. 50, No. 1, (Apr 2004), pp. (3-22), Review 
Pietras, R.J. & Szego, C.M. (1977). Specific binding sites for oestrogen at the outer surfaces of 
isolated endometrial cells. Nature, Vol. 265, No. 5589, (Jan 1977), pp. (69-72) 
Pietschmann, P., Rauner, M., Sipos, W. & Kerschan-Schindl K. (2008). Osteoporosis: an age-
related and gender-specific disease - a mini-review. Gerontology, Vol. 55, No. 1, pp. 
(3-12)  
Ray, A., Préfontaine, K.E. & Ray, P. (1994). Down-modulation of interleukin-6 gene 
expression by 17beta-estradiol in the absence of high affinity DNA binding by the 
estrogen receptor. J. Biol. Chem., Vol. 269, No. 17, (Apr 1994), pp. (12940-12946)  
Razandi, M., Pedram, A., Greene, G.L. & Levin, E.R. (1999). Cell membrane and nuclear 
estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and 
ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol., Vol. 13, No. 2, 
(Feb 1999), pp. (307-319)  
Reginster, J.Y., Kvasz, A., Bruyère, O. & Henrotin, Y. (2003). Is there any rationale for 
prescribing hormone replacement therapy (HRT) to prevent or to treat 
osteoarthritis? Osteoarthritis Cartilage, Vol.,11, No. 2, (Feb 2003), pp. (87-91) 
Richette, P., Corvol, M. & Bardin, T. (2003). Estrogens, cartilage, and osteoarthritis. Joint Bone 
Spine, Vol. 70, No. 4, (Aug 2003), pp. (257-262)  
Richette, P. Dumontier, M.F., Francois, M., Tsagris, L., Korwin-Zmijowska, C., Rannou, F. & 
Corvol, M.T. (2004). Dual effects of 17beta-oestradiol on interleukin 1beta-induced 
www.intechopen.com
 
Challenges in Rheumatology 60
proteoglycan degradation in chondrocytes.  Ann. Rheum. Dis., Vol. 63, No. 2, (Feb 
2004), pp. (191-199)  
Richette, P., Dumontier, M.F., Tahiri, K., Widerak, M., Torre, A., Benallaoua, M., Rannou, F., 
Corvol, M.T. & Savouret, J.F. (2007). Oestrogens inhibit interleukin 1beta-mediated 
nitric oxide synthase expression in articular chondrocytes through nuclear factor-
kappa B impairment. Ann. Rheum. Dis., Vol. 66, No. 3, (Mar 2007), pp. (345-350)  
Richmond, R.S., Carlson, C.S., Register, T.C., Shanker, G. & Loeser, R.F. (2000). Functional 
estrogen receptors in adult articular cartilage: estrogen replacement therapy 
increases chondrocyte synthesis of proteoglycans and insulin-like growth factor 
binding protein 2. Arthritis Rheum., Vol. 43, No. 9, (Sep 2000), pp. (2081-2090)  
Riggs, B.L. & Hartmann L.C. (2003). Selective estrogen-receptor modulators - mechanisms of 
action and application to clinical practice. N Engl J Med, Vol.,348, No.7, (Feb 2003), 
pp. (618–629)  
Sabbah, M., Courilleau, D., Mester, J. & Redeuilh, G. (1999). Estrogen induction of the cyclin 
D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. 
U. S. A., Vol. 96, No. 20, (Sep 1999), pp. (11217-11222)  
Safe, S. (2001). Transcriptional activation of genes by 17 beta-estradiol through estrogen 
receptor-Sp1 interactions. Vitam. Horm., Vol. 62, pp. (231-252)  
Saggese, G., Federico, G. & Cinquanta, L. (1993). In vitro effects of growth hormone and 
other hormones on chondrocytes and osteoblast-like cells. Acta Paediatr. Suppl, Vol. 
82, Suppl. 391, (Sep 1993), pp. (54-59)  
Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J.A. & 
Safe, S. (2000). Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-
dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem., Vol. 275, 
No. 8, (Feb 2000), pp.  (5379-5387)  
Simpson, E.R. (2003). Sources of estrogen and their importance. J. Steroid Biochem., Mol. Biol., 
Vol. 86, No. 3-5, (Sep 2003), pp. (225-230)  
Sniekers, Y.H., Intema, F., Lafeber, F.P., Van Osch, G.J., Van Leeuwen, J.P., Weinans, H. & 
Mastbergen, S.C. (2008). A role for subchondral bone changes in the process of 
osteoarthritis; a micro-CT study of two canine models. BMC Musculoskelet. Disord., 
(Feb 2008), pp. (9-20)  
Sniekers, Y.H., Van Osch, G.J., Ederveen, A.G., Inzunza, J., Gustafsson, J.A., Van Leeuwen, 
J.P. & Weinans, H. (2009). Development of osteoarthritic features in estrogen 
receptor knockout mice. Osteoarthritis Cartilage, Vol. 17, No. 10, (Oct 2009), pp. 
(1356-1361)  
Stein, B. & Yang, M.X. (1995). Repression of the interleukin-6 promoter by estrogen receptor 
is mediated by NF-kappa B and C/EBP beta. Mol. Cell Biol., Vol. 15, No. 9, (Sep 
1995), pp. (4971-4979)  
Song, Y.J., Wu, Z.H., Lin, S.Q., Weng, X.S. & Qiu, G.X. (2003). The effect of estrogen and 
progestin on the expression of matrix metalloproteinases, tissue inhibitor of 
metalloproteinase and interleukin-1beta mRNA in synovia of OA rabbit model. 
Zhonghua Yi. Xue. Za Zhi., Vol. 83, No. 6, (Mar 2003), pp. (498-503)  
Spector, T.D., Brown, G.C. & Silman, A.J. (1988). Increased rates of previous hysterectomy 
and gynecological operations in women with osteoarthritis. BMJ, Vol. 297, No. 
6653, (Oct 1988), pp. (899–900)  
www.intechopen.com
 
Estrogens Involvement in the Physiopathology of Articular Cartilage 61 
Spector, T.D., Hart, D.J., Brown, P., Almeyda, J., Dacre, J.E., Doyle, D.V. & Silman, A.J. 
(1991). Frequency of osteoarthritis in hysterectomized women. J Rheumatol., Vol. 18, 
No. 12, (Dec 1991), pp. (1877–1883)  
Stoner, M., Wormke, M., Saville, B., Samudio, I., Qin, C., Abdelrahim, M. & Safe, S. (2004). 
Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 
breast cancer cells through interaction of estrogen receptor alpha and SP proteins. 
Oncogene, Vol. 23, No. 5, (Feb 2004), pp. (1052-1063)  
Stovall, D.W. & Pinkerton, J.V. (2008). Estrogen agonists/antagonists in combination with 
estrogen for prevention and treatment of menopause-associated signs and 
symptoms. Womens Health (Lond Engl), Vol. 4, No. 3, (May 2008), pp. (257-268) 
Stracke, D., Schulz, T. & Prehm, P. (2011). Inhibitors of hyaluronan export from hops 
prevent osteoarthritic reactions. Mol Nutr Food Res. Vol. 55, No. 3, (Mar 2011), pp. 
(485-494) 
Takeuchi, S., Mukai, N., Tateishi, T. & Miyakawa, S. (2007). Production of sex steroid 
hormones from DHEA in articular chondrocyte of rats. Am. J. Physiol. Endocrinol. 
Metab., Vol. 293, No. 1, (Jul 2007), pp. (E410-E415) 
Tanko, L.B., Sondergaard, B.C., Oestergaard, S., Karsdal, M.A. & Christiansen, C. (2008). An 
update review of cellular mechanisms conferring the indirect and direct effects of 
estrogen on articular cartilage. Climacteric, Vol. 11, No. 1, (Feb 2008), pp. (4-16)  
Toft, D. & Gorski, J. (1966). A receptor molecule for estrogens: isolation from the rat uterus 
and preliminary characterization. Proc. Natl. Acad. Sci. U. S. A., Vol. 55, No. 6, (Jun 
1966), pp. (1574-1581)  
Tsai, C.L., Liu, T.K. & Chen, T.J. (1992). Estrogen and osteoarthritis: a study of synovial 
estradiol and estradiol receptor binding in human osteoarthritic knees. Biochem 
Biophys Res Commun., Vol. 183, No. 3, (Mar 1992), pp. (1287-1291) 
Uht, R.M., Anderson, C.M., Webb, P. & Kushner, P.J. (1997). Transcriptional activities of 
estrogen and glucocorticoid receptors are functionally integrated at the AP-1 
response element. Endocrinology, Vol. 138, No. 7, (Jul 1997), pp. (2900-2908)  
 Valdes, A.M., Van Oene, M., Hart, D.J., Surdulescu, G.L., Loughlin, J., Doherty, M. & 
Spector, T.D. (2006). Reproducible genetic associations between candidate genes 
and clinical knee osteoarthritis in men and women. Arthritis Rheum., Vol. 54, No. 2, 
(Feb 2006), pp. (533-539)  
Von Muhlen, D., Morton, D., Von Muhlen, C.A. & Barrett-Connor, E. (2002). 
Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, 
hand, and knee in older women. J. Womens Health Gend. Based. Med., Vol. 11, No. 6, 
(Jul-Aug 2002), pp. (511-518)  
Walter, P., Green, S., Greene, G., Krust, A., Bornert, J.M., Jeltsch, J.M., Staub, A., Jensen, E., 
Scrace, G., Waterfield, M. & Chambon P. (1985). Cloning of the human estrogen 
receptor cDNA. Proc. Natl. Acad. Sci. U. S. A., Vol. 82, No. 23, (Dec 1985), pp. (7889-
7893) 
Wang, Z., Zhang, X., Shen, P., Loggie, B.W., Chang, Y. & Deuel, T.F. (2006). A variant of 
estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and 
antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. 
Sci. U. S. A., Vol. 103, No. 24, (Jun 2006), pp. (9063-9068)  
www.intechopen.com
 
Challenges in Rheumatology 62
Webb, P., Nguyen, P., Valentine, C, Lopez, G.N., Kwok, G.R., McInerney, E., 
Katzenellenbogen, B.S., Enmark, E., Gustafsson, J.A., Nilsson, S. & Kushner, P.J. 
(1999). The estrogen receptor enhances AP-1 activity by two distinct mechanisms 
with different requirements for receptor transactivation functions. Mol. Endocrinol., 
Vol. 13, No. 10, (Oct 1999), pp. (1672-1685)  
Wilson, M.G., Michet, C.J. Jr., Ilstrup, D.M. & Melton, L.J. (1990). Idiopathic symptomatic 
osteoarthritis of the hip and knee: A population-based incidence study. Mayo Clin 
Proc.,  Vol. 65, No. 9, (Sep 1990), pp. (1214-1221) 
Wluka, A.E., Davis, S.R., Bailey, M., Stuckey, S.L. & Cicuttini, F.M. (2001). Users of oestrogen 
replacement therapy have more knee cartilage than non-users. Ann. Rheum. Dis., 
Vol. 60, No. 4, (Apr 2001), pp. (332-336) 
www.intechopen.com
Challenges in Rheumatology
Edited by Dr. Miroslav Harjacek
ISBN 978-953-307-848-9
Hard cover, 190 pages
Publisher InTech
Published online 22, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Rheumatology is a subspecialty of medicine that focuses on the biology, cause, diagnosis and the treatment of
a variety of musculoskeletal and other systemic diseases. The field of rheumatology is expanding rapidly and
several very exciting developments have occurred during the recent years. Firstly, there has been a new
dramatic understanding of the nature of inflammation and the possibility of specifically regulating the aberrant
immune inflammatory response. Secondly, an understanding of pathogenesis has lead to the development of
new, more targeted therapies. Challenges in Rheumatology has assembled an impressive group of
international experts who have studied specific aspects of certain rheumatic diseases and have extensive
experience either in pathophysiology, or with the in-depth diagnosis and/or management of rheumatic patients.
They communicate their knowledge and experience to the reader in chapters that are conveniently organized
as pathophysiology, clinical manifestations and diagnosis of selected rheumatic diseases, medical and
perioperative orthopedic management, and the economic impact of rheumatic diseases. We hope that this
book will help trainees become better physicians and scientists, and that it will help practicing rheumatologists
to provide better care, and ultimately, improve the quality of life of our patients.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Moslemi Safa, Demoor Magali, Boumediene Karim, Galera Philippe and Maneix Laure (2011). Estrogens
Involvement in the Physiopathology of Articular Cartilage, Challenges in Rheumatology, Dr. Miroslav Harjacek
(Ed.), ISBN: 978-953-307-848-9, InTech, Available from: http://www.intechopen.com/books/challenges-in-
rheumatology/estrogens-involvement-in-the-physiopathology-of-articular-cartilage
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
